SLC5A2 and hydrops fetalis: These trends might appear to reflect recent significant advances in HF management, including the widespread adoption of innovative medications such as ARNI and SGLT2 inhibitors, the evolution of mechanical support devices, as well as continuous optimization of clinical guidelines.